# A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

> **NCT03029832** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** MOXR0916
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03029832
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-27
- **Primary completion:** 2018-04-25
- **Final completion:** 2018-04-25
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was prematurely terminated due to slow patient accrual and discontinuation of clinical development of MOXR0916 due to Sponsor's strategic priorities.
- **Last updated:** 2019-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029832, "A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03029832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*